Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MASP2 | O00187 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58001 | 1.00 | ALDH1A1 (0.60) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL30634854 | 0.75 | NPC1 (1.00) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL30561047 | 0.75 | NPC1 (1.00) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL172216 | 0.75 | NPC1 (1.00) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL29034384 | 0.73 | ALDH1A1 (0.62) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| Water SCHEMBL9817804 | 0.73 | NPC1 (0.95) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL2706718 | 0.71 | ALDH1A1 (0.60) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL277761 | 0.71 | ALDH1A1 (0.60) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL460600 | 0.71 | ALDH1A1 (0.61) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL2589250 | 0.71 | ALDH1A1 (0.60) | ALDH1A1KDM4ENPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996574-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | claimed |
| WO-2007103554-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | claimed |
| EP-0749419-A1 | OXIME DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AG (DE) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024383-A1 | OXIME DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-14 | — | — | WO | claimed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | claimed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | claimed |
| EP-0096795-A2 | N-aryl pyridones, their preparation and use | BAYER AG (DE) | 1983-12-28 | — | — | EP | claimed |
| EP-0029202-B1 | NOVEL TETRAZOLE-5-THIOL ESTERS AND PROCESS FOR PREPARING CEFAMANDOLE USING SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-04-13 | — | — | EP | claimed |
| JP-56073086-A | — | — | None | — | — | JP | disclosed |
| EP-3901235-B1 | ORGANIC ELECTROLUMINESCENT DEVICES AND METAL COMPLEX COMPOUNDS | UDC IRELAND LTD (IE) | 2023-11-15 | — | — | EP | disclosed |
| EP-3741768-B1 | STABILIZED IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORP (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11393989-B2 | Organic electroluminescent devices and metal complex compounds | UDC IRELAND LIMITED (IE) | 2022-07-19 | — | — | US | disclosed |
| EP-3901235-A1 | ORGANIC ELECTROLUMINESCENT DEVICES AND METAL COMPLEX COMPOUNDS | UDC Ireland Limited (IE) | 2021-10-27 | — | — | EP | disclosed |
| EP-0096795-A2 | N-aryl pyridones, their preparation and use | BAYER AG (DE) | 1983-12-28 | — | — | EP | disclosed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | disclosed |
| US-4410618-A | DEVELOPMENT INHIBITORS | EASTMAN KODAK COMPANY (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0076452-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1983-04-13 | — | — | EP | disclosed |
| EP-0070803-A2 | Antibiotically active aminotriazolylcephalosporin derivatives and their preparation | CIBA-GEIGY AG (CH) | 1983-01-26 | — | — | EP | disclosed |
| JP-S5673086-A | PREPARATION OF CEPHALOSPORIN COMPOUND | ASAHI CHEM IND CO LTD | 1981-06-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE10A, PDE4A | ALDH1A1 716/4885KDM4E 1286/4885NPC1 2604/4885 |
| US-11393989-B2 | Organic electroluminescent devices and metal complex compounds | EPCAM, TPR, L1CAM | ALDH1A1 2524/4885KDM4E 1698/4885NPC1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.